Takeda Ukraine Awarded Best Place to Work Certification in 2024
Takeda Ukraine has been awarded the Best Place to Work certification for 2024 in Ukraine, showcasing its dedication to employee well-being, professional development, and diversity. The company’s commitment to employee satisfaction is evident in its benefits package, learning opportunities, and inclusivity initiatives. With a focus on innovation and collaboration, Takeda Ukraine empowers employees to make a positive impact on patient care. The General Manager and Head of HR expressed pride in the achievement, highlighting the organization’s exceptional culture and dedication. As Takeda Ukraine continues to enhance its workplace culture, it aims to set a high standard for workplace excellence in Ukraine and beyond.
WHO Prequalifies TAK-003: New Dengue Vaccine Marks Major Breakthrough
The World Health Organization (WHO) prequalified the innovative TAK-003 dengue vaccine, designed for children aged 6-16 in high-prevalence regions. With a two-dose regimen, TAK-003 joins the WHO list alongside CYD-TDV, expanding global vaccine accessibility. Dengue, a significant public health threat, affects millions annually, highlighting the importance of advancements in vaccine development.
Conditional Approval Granted to Takeda’s Qdenga Dengue Vaccine
The Drug Control Authority has granted conditional approval to Takeda’s Qdenga dengue vaccine, recommended by the World Health Organization to combat the alarming spike in dengue cases. With a reported 86.3% increase in cases and 100 deaths in 2023, the approval of the vaccine is a crucial development in addressing the public health menace of dengue fever.
Malaysia Urged to Consider Approval of New Dengue Vaccine
The Health Ministry of Malaysia is urged to consider approving a newly released dengue vaccine to combat the increasing number of cases in the country, according to Datuk Dr Lam Sai Kit, a virologist and Universiti Malaya emeritus professor. Dr….